You might also like
Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations, primarily targeting structural heart disease and critical care monitoring . The company operates in several geographical regions, including the United States, Europe, Japan, and the Rest of the World . They sell products categorized into four main groups: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care . In 2023, TAVR was a significant driver of revenue growth, and the company has announced plans to spin off its Critical Care product group to focus more on TAVR, TMTT, and Surgical innovations .
- Transcatheter Aortic Valve Replacement (TAVR) - Provides minimally invasive procedures for replacing aortic valves, significantly contributing to revenue growth.
- Surgical Structural Heart - Offers surgical solutions for heart valve repair and replacement, showing strong sales performance.
- Transcatheter Mitral and Tricuspid Therapies (TMTT) - Focuses on developing innovative therapies for mitral and tricuspid valve diseases.
- Critical Care - Delivers advanced hemodynamic monitoring systems and disposable pressure transducers, with plans for a spin-off to concentrate on other segments.
-
Given the increasing competition in the TAVR market, including the potential entry of a fourth valve and instances of regional pricing pressure, how do you plan to sustain your premium pricing strategy and market share while differentiating your products in an increasingly crowded field?
-
With hospitals facing ongoing heart team capacity constraints that may limit TAVR procedure volumes, what specific initiatives are you implementing to address these limitations, and how confident are you that hospitals will invest to expand capacity in line with your growth expectations?
-
Considering the FTC's second request and the anticipated mid-2025 closing of the JenaValve acquisition, what risks do you foresee in the regulatory review process, and how might potential delays impact your strategy to address the unmet needs in aortic regurgitation?
-
As you scale your TMTT business with strong adoption of PASCAL and EVOQUE, how are you managing the significant investments in training, clinical support, and field team expansion, and when do you anticipate this segment achieving profitability?
-
Can you provide more details on the one-time rebate adjustment in China and discuss any underlying challenges in that market, including how slower growth in regions like Japan might influence your international TAVR sales trajectory going forward?
Competitors mentioned in the company's latest 10K filing.
- Medtronic PLC - Competitor in Transcatheter Aortic Valve Replacement and Surgical Structural Heart .
- Abbott Laboratories - Competitor in Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Surgical Structural Heart .
- Boston Scientific Corporation - Competitor in Transcatheter Aortic Valve Replacement .
- Artivion, Inc (formerly CryoLife) - Competitor in Surgical Structural Heart .
- ICU Medical, Inc. - Competitor in Critical Care .
- PULSION Medical Systems SE, a subsidiary of Getinge AB - Competitor in Critical Care .
- Cheetah Medical, Inc., a subsidiary of Baxter International - Competitor in Critical Care .
- LiDCO Group PLC, a subsidiary of Masimo Corporation - Competitor in Critical Care .